|کد مقاله||سال انتشار||مقاله انگلیسی||ترجمه فارسی||تعداد کلمات|
|117096||2017||28 صفحه PDF||سفارش دهید||6779 کلمه|
Publisher : Elsevier - Science Direct (الزویر - ساینس دایرکت)
Journal : Journal of Anxiety Disorders, Volume 45, January 2017, Pages 80-86
We compared persons participating in clinical trials with a principal diagnosis of SHA (NÂ =Â 290) to persons with a principal diagnosis of OCD (nÂ =Â 95) on measures of health anxiety, OCD symptoms, and depressive symptoms. A subsample of SHA participants (nÂ =Â 99) received exposure and response prevention (ERP) for SHA over 12 weeks and was assessed at baseline and post-treatment. The results showed large and significant differences between SHA and OCD patients on measures of health anxiety (dsÂ =Â 2.99â3.09) and OCD symptoms (dsÂ =Â 1.64â2.14), while they had equivalent levels of depressive symptoms (dÂ =Â 0.19, 95% CI [â0.04, 0.43]). In the SHA sample 7.6% had comorbid OCD, and in the OCD sample 9.5% had SHA. For participants with a principal diagnosis of SHA, ERP led to large reductions of health anxiety, but effects on OCD symptoms were small to moderate. Among participants with comorbid OCD, effect sizes were large on measures of health anxiety and moderate to large on OCD measures. We conclude that SHA and OCD are separate psychiatric disorders with limited overlap in symptom profiles.